Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association
Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely with rapidly progressive pneumonia, fungemia, or man...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
PAGEPress Publications
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a2c92240702f4e08a388d4bac8cdc68f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a2c92240702f4e08a388d4bac8cdc68f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a2c92240702f4e08a388d4bac8cdc68f2021-11-26T14:38:44ZTherapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association10.4081/hr.2021.93292038-83222038-8330https://doaj.org/article/a2c92240702f4e08a388d4bac8cdc68f2021-11-01T00:00:00Zhttps://www.pagepress.org/journals/index.php/hr/article/view/9329https://doaj.org/toc/2038-8322https://doaj.org/toc/2038-8330 Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely with rapidly progressive pneumonia, fungemia, or manifestations of extrapulmonary dissemination. Opportunistic fungal infections (mycoses) include several pathogens elements, as Candidiasis, Aspergillosis, Mucormycosis (zygomycosis) and Fusariosis. Prompt diagnosis and effective therapy are needed to improve the associated morbidity and mortality, especially in cases with non-canonical fungal localizations and not responsive to the available antifungal drugs. Andrea DuminucoElisa MauroGiuseppe A. M. PalumboBruno GaribaldiMarina ParisiFrancesco Di RaimondoCinzia MaugeriCalogero VetroPAGEPress PublicationsarticleFungal infectionCandidaisavuconazolecaspofungincombined antifungal therapyhematological patientsDiseases of the blood and blood-forming organsRC633-647.5ENHematology Reports, Vol 13, Iss 4 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Fungal infection Candida isavuconazole caspofungin combined antifungal therapy hematological patients Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Fungal infection Candida isavuconazole caspofungin combined antifungal therapy hematological patients Diseases of the blood and blood-forming organs RC633-647.5 Andrea Duminuco Elisa Mauro Giuseppe A. M. Palumbo Bruno Garibaldi Marina Parisi Francesco Di Raimondo Cinzia Maugeri Calogero Vetro Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| description |
Fungal infections occurring in immunocompromised patients after immuno-chemotherapy treatment, are often difficult to eradicate and capable of even being fatal. Systemic mycoses affecting severely immunocompromised patients often manifest acutely with rapidly progressive pneumonia, fungemia, or manifestations of extrapulmonary dissemination. Opportunistic fungal infections (mycoses) include several pathogens elements, as Candidiasis, Aspergillosis, Mucormycosis (zygomycosis) and Fusariosis. Prompt diagnosis and effective therapy are needed to improve the associated morbidity and mortality, especially in cases with non-canonical fungal localizations and not responsive to the available antifungal drugs.
|
| format |
article |
| author |
Andrea Duminuco Elisa Mauro Giuseppe A. M. Palumbo Bruno Garibaldi Marina Parisi Francesco Di Raimondo Cinzia Maugeri Calogero Vetro |
| author_facet |
Andrea Duminuco Elisa Mauro Giuseppe A. M. Palumbo Bruno Garibaldi Marina Parisi Francesco Di Raimondo Cinzia Maugeri Calogero Vetro |
| author_sort |
Andrea Duminuco |
| title |
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| title_short |
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| title_full |
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| title_fullStr |
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| title_full_unstemmed |
Therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| title_sort |
therapeutic innovation for multi-resistant candidemics: synergy of isavuconazole and caspofungin association |
| publisher |
PAGEPress Publications |
| publishDate |
2021 |
| url |
https://doaj.org/article/a2c92240702f4e08a388d4bac8cdc68f |
| work_keys_str_mv |
AT andreaduminuco therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT elisamauro therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT giuseppeampalumbo therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT brunogaribaldi therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT marinaparisi therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT francescodiraimondo therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT cinziamaugeri therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation AT calogerovetro therapeuticinnovationformultiresistantcandidemicssynergyofisavuconazoleandcaspofunginassociation |
| _version_ |
1718409308996108288 |